These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30085300)

  • 21. High-throughput screen identifies 5-HT receptor as a modulator of AR and a therapeutic target for prostate cancer.
    Itsumi M; Shiota M; Sekino Y; Ushijima M; Kashiwagi E; Takeuchi A; Inokuchi J; Kajioka S; Uchiumi T; Eto M
    Prostate; 2020 Aug; 80(11):885-894. PubMed ID: 32483877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression.
    Zhang Y; Pitchiaya S; Cieślik M; Niknafs YS; Tien JC; Hosono Y; Iyer MK; Yazdani S; Subramaniam S; Shukla SK; Jiang X; Wang L; Liu TY; Uhl M; Gawronski AR; Qiao Y; Xiao L; Dhanasekaran SM; Juckette KM; Kunju LP; Cao X; Patel U; Batish M; Shukla GC; Paulsen MT; Ljungman M; Jiang H; Mehra R; Backofen R; Sahinalp CS; Freier SM; Watt AT; Guo S; Wei JT; Feng FY; Malik R; Chinnaiyan AM
    Nat Genet; 2018 Jun; 50(6):814-824. PubMed ID: 29808028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells.
    Ngan S; Stronach EA; Photiou A; Waxman J; Ali S; Buluwela L
    Oncogene; 2009 May; 28(19):2051-63. PubMed ID: 19363526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
    Rosati R; Polin L; Ducker C; Li J; Bao X; Selvakumar D; Kim S; Xhabija B; Larsen M; McFall T; Huang Y; Kidder BL; Fribley A; Saxton J; Kakuta H; Shaw P; Ratnam M
    Clin Cancer Res; 2018 Dec; 24(24):6509-6522. PubMed ID: 30185422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ING3 promotes prostate cancer growth by activating the androgen receptor.
    Nabbi A; McClurg UL; Thalappilly S; Almami A; Mobahat M; Bismar TA; Binda O; Riabowol KT
    BMC Med; 2017 May; 15(1):103. PubMed ID: 28511652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen-dependent regulation of Her-2/neu in prostate cancer cells.
    Berger R; Lin DI; Nieto M; Sicinska E; Garraway LA; Adams H; Signoretti S; Hahn WC; Loda M
    Cancer Res; 2006 Jun; 66(11):5723-8. PubMed ID: 16740710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells.
    Liu P; Li S; Gan L; Kao TP; Huang H
    Cancer Res; 2008 Dec; 68(24):10290-9. PubMed ID: 19074897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.
    Malinowska K; Cavarretta IT; Susani M; Wrulich OA; Uberall F; Kenner L; Culig Z
    Prostate; 2009 Jul; 69(10):1109-18. PubMed ID: 19353593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells.
    Takayama K; Tsutsumi S; Katayama S; Okayama T; Horie-Inoue K; Ikeda K; Urano T; Kawazu C; Hasegawa A; Ikeo K; Gojyobori T; Ouchi Y; Hayashizaki Y; Aburatani H; Inoue S
    Oncogene; 2011 Feb; 30(5):619-30. PubMed ID: 20890304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen Receptor Splice Variants Are Not Substrates of Nonsense-Mediated Decay.
    Ajiboye AS; Esopi D; Yegnasubramanian S; Denmeade SR
    Prostate; 2017 Jun; 77(8):829-837. PubMed ID: 28224650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
    Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells.
    Li TH; Zhao H; Peng Y; Beliakoff J; Brooks JD; Sun Z
    Nucleic Acids Res; 2007; 35(8):2767-76. PubMed ID: 17426117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
    Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cells.
    Margiotti K; Wafa LA; Cheng H; Novelli G; Nelson CC; Rennie PS
    Mol Cancer; 2007 Jun; 6():38. PubMed ID: 17553164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line.
    Marcias G; Erdmann E; Lapouge G; Siebert C; Barthélémy P; Duclos B; Bergerat JP; Céraline J; Kurtz JE
    Hum Mutat; 2010 Jan; 31(1):74-80. PubMed ID: 19830810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen receptor structural and functional elements: role and regulation in prostate cancer.
    Dehm SM; Tindall DJ
    Mol Endocrinol; 2007 Dec; 21(12):2855-63. PubMed ID: 17636035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.
    Marques RB; Erkens-Schulze S; de Ridder CM; Hermans KG; Waltering K; Visakorpi T; Trapman J; Romijn JC; van Weerden WM; Jenster G
    Int J Cancer; 2005 Nov; 117(2):221-9. PubMed ID: 15900601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development.
    Moehren U; Papaioannou M; Reeb CA; Grasselli A; Nanni S; Asim M; Roell D; Prade I; Farsetti A; Baniahmad A
    FASEB J; 2008 Apr; 22(4):1258-67. PubMed ID: 17991730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The RNA helicase DDX39B and its paralog DDX39A regulate androgen receptor splice variant AR-V7 generation.
    Nakata D; Nakao S; Nakayama K; Araki S; Nakayama Y; Aparicio S; Hara T; Nakanishi A
    Biochem Biophys Res Commun; 2017 Jan; 483(1):271-276. PubMed ID: 28025139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.